Swann Gaulis
Novartis
12 Papers
47 Citations
Swann Gaulis is an academic researcher from Novartis. The author has contributed to research in topics: Cancer & Acquired immune system. The author has an hindex of 9, co-authored 12 publications.
Chat about Author
Papers
Immune cell landscaping reveals a protective role for regulatory T cells during kidney injury and fibrosis.
Fernanda do Valle Duraes,Armelle Lafont,Martin Beibel,Kea Martin,Katy Darribat,Rachel Cuttat,Annick Waldt,Ulrike Naumann,Grazyna Wieczorek,Swann Gaulis,Sabina Pfister,Kirsten D. Mertz,Jianping Li,Guglielmo Roma,Max Warncke +14 more
TL;DR: The data point to a hitherto underappreciated plasticity in Treg function within the same tissue, dictated by environmental cues, as well as a detailed cellular and molecular characterization of the immunological changes during kidney injury, regeneration, and fibrosis.
A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097
Sébastien Jeay,Swann Gaulis,Stephane Ferretti,Hans Bitter,Moriko Ito,Thérèse Valat,Masato Murakami,Stephan Ruetz,Daniel Guthy,Caroline Rynn,Michael Rugaard Jensen,Marion Wiesmann,Joerg Kallen,Pascal Furet,François Gessier,Philipp Holzer,Keiichi Masuya,Jens Würthner,Ensar Halilovic,Francesco Hofmann,William R. Sellers,Diana Graus Porta +21 more
TL;DR: Evidence is provided for the use of this newly identified predictive gene signature to refine the selection of patients with wild-type p53 tumors and increase the likelihood of response to treatment with p53–HDM2 inhibitors, such as NVP-CGM097.
87
PAX8 activates metabolic genes via enhancer elements in Renal Cell Carcinoma.
Melusine Bleu,Swann Gaulis,Rui Lopes,Kathleen Sprouffske,Verena Apfel,Sjoerd J B Holwerda,Marco Pregnolato,Marco Pregnolato,Umut Yildiz,Umut Yildiz,Valentina Cordoʹ,Antonella F M Dost,Antonella F M Dost,Judith Knehr,Walter Carbone,Felix Lohmann,Charles Y. Lin,James E. Bradner,Audrey Kauffmann,Luca Tordella,Guglielmo Roma,Giorgio G. Galli +21 more
TL;DR: Computational and functional genomic approaches are used to show an oncogenic role of PAX8 in renal cancer and a potential biomarker to monitor its activity is provided.
Identification of elongation factor G as the conserved cellular target of argyrin B.
Beat Nyfeler,Dominic Hoepfner,Deborah Palestrant,Christina A. Kirby,Lewis Whitehead,Robert Yu,Gejing Deng,Ruth E. Caughlan,Angela L. Woods,Adriana K. Jones,S. Whitney Barnes,John R. Walker,Swann Gaulis,Ervan Hauy,Saskia M. Brachmann,Philipp Krastel,Christian Studer,Ralph Riedl,David Estoppey,Thomas Aust,N. Rao Movva,Zuncai Wang,Michael Salcius,Gregory A. Michaud,Gregory McAllister,Leon Murphy,John A. Tallarico,Christine D. Wilson,Charles R. Dean +28 more
TL;DR: It is shown that argyrin B is an antibacterial and cytotoxic agent that inhibits the evolutionarily conserved target EF-G, blocking protein synthesis in bacteria and mitochondrial translation in yeast and mammalian cells.
Abstract 5560: PD-1/PD-L1 blockade enhances MDM2 inhibitor activity in p53 wild-type cancers
Hui Qin Wang,Jinsheng Liang,Iain Mulford,Fiona Sharp,Swann Gaulis,Yan Chen,Gina Trabucco,David Quinn,Joseph D. Growney,Matthew J. Meyer,Juliet Williams,Peter S. Hammerman,Francesco Hofmann,Glenn Dranoff,Jeffrey A. Engelman,Jennifer Marie Mataraza,Ensar Halilovic +16 more
TL;DR: Results demonstrate that MDM2 inhibition triggered adaptive immunity which was further enhanced by blockade of PD-1/PD-L1 pathway, thereby providing a rationale for combiningMDM2 inhibitors and checkpoint blocking antibodies in cancer patients with wildtype p53.
3